Liberum Capital Reiterates Buy Rating for AstraZeneca plc (AZN)
AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reiterated by research analysts at Liberum Capital in a research report issued to clients and investors on Monday. They presently have a GBX 5,500 ($70.65) price target on the biopharmaceutical company’s stock. Liberum Capital’s price objective indicates a potential upside of 2.39% from the company’s current price.
Other research analysts have also recently issued reports about the stock. BNP Paribas reaffirmed a “neutral” rating and set a GBX 5,300 ($68.08) target price on shares of AstraZeneca plc in a report on Monday, April 3rd. HSBC Holdings plc reaffirmed a “reduce” rating and set a GBX 4,200 ($53.95) target price on shares of AstraZeneca plc in a report on Friday, May 5th. Shore Capital reaffirmed a “sell” rating on shares of AstraZeneca plc in a report on Wednesday, May 10th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of AstraZeneca plc in a report on Thursday, May 11th. Finally, Berenberg Bank raised their target price on shares of AstraZeneca plc from GBX 5,670 ($72.83) to GBX 5,850 ($75.14) and gave the stock a “buy” rating in a report on Wednesday, May 17th. Six equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of GBX 5,026.80 ($64.57).
Shares of AstraZeneca plc (AZN) opened at 5342.35 on Monday. The firm’s 50-day moving average price is GBX 4,912.60 and its 200-day moving average price is GBX 4,614.19. The firm’s market capitalization is GBX 67.63 billion. AstraZeneca plc has a 12-month low of GBX 3,680.00 and a 12-month high of GBX 5,505.00.
TRADEMARK VIOLATION NOTICE: This piece was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/06/05/liberum-capital-reiterates-buy-rating-for-astrazeneca-plc-azn.html.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.